KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash & Equivalents (2017 - 2025)

Novartis Ag (NVS) has disclosed Cash & Equivalents for 9 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 77.49% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Dec 2025, down 77.49% year-over-year, with the annual reading at $2.6 billion for FY2025, 77.49% down from the prior year.
  • Cash & Equivalents hit $2.6 billion in Q4 2025 for Novartis Ag, down from $11.5 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $13.4 billion in Q4 2023 to a low of $2.6 billion in Q4 2025.
  • Historically, Cash & Equivalents has averaged $9.5 billion across 5 years, with a median of $11.5 billion in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 78.17% in 2023 and later plummeted 77.49% in 2025.
  • Year by year, Cash & Equivalents stood at $12.4 billion in 2021, then tumbled by 39.41% to $7.5 billion in 2022, then skyrocketed by 78.17% to $13.4 billion in 2023, then fell by 14.44% to $11.5 billion in 2024, then tumbled by 77.49% to $2.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for NVS at $2.6 billion in Q4 2025, $11.5 billion in Q4 2024, and $13.4 billion in Q4 2023.